Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020230136 - ACSS2 INHIBITORS AND METHODS OF USE THEREOF

Publication Number WO/2020/230136
Publication Date 19.11.2020
International Application No. PCT/IL2020/050526
International Filing Date 14.05.2020
IPC
C07D 231/26 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02not condensed with other rings
10having two or three double bonds between ring members or between ring members and non-ring members
14with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
18One oxygen or sulfur atom
20One oxygen atom attached in position 3 or 5
22with aryl radicals attached to ring nitrogen atoms
261-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
C07D 401/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
C07D 401/10 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
C07D 401/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 401/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 403/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Applicants
  • METABOMED LTD [IL]/[IL]
Inventors
  • NAKACHE, Philippe
  • EREZ, Omri
  • BOTTI, Simone
  • GOUTOPOULOS, Andreas
Agents
  • COHEN, Mark, S.
  • COHEN, Mark S.
Priority Data
16/411,16814.05.2019US
62/847,34814.05.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ACSS2 INHIBITORS AND METHODS OF USE THEREOF
(FR) INHIBITEURS D'ACSS2 ET LEURS PROCÉDÉS D'UTILISATION
Abstract
(EN)
The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.
(FR)
La présente invention concerne de nouveaux inhibiteurs d'ACSS2 ayant une activité dans la lutte contre le cancer, le traitement de l'alcoolisme, et l'infection virale (par exemple, CMV), une composition et des procédés de préparation de ceux-ci, ainsi que leurs utilisations dans le traitement d'une infection virale, de l'alcoolisme, la stéatohépatite alcoolique (ASH), la stéatohépatite non alcoolique (NASH), l'obésité/la prise de poids, l'anxiété, la dépression, le trouble de stress post-traumatique, les affections inflammatoires/auto-immunes et le cancer, y compris le cancer métastatique, le cancer avancé, et le cancer résistant aux médicaments de divers types.
Latest bibliographic data on file with the International Bureau